GT201200284A - Composición farmacéutica - Google Patents

Composición farmacéutica

Info

Publication number
GT201200284A
GT201200284A GT201200284A GT201200284A GT201200284A GT 201200284 A GT201200284 A GT 201200284A GT 201200284 A GT201200284 A GT 201200284A GT 201200284 A GT201200284 A GT 201200284A GT 201200284 A GT201200284 A GT 201200284A
Authority
GT
Guatemala
Prior art keywords
pharmaceutical composition
efavirenz
understands
nanoparticles
pharmaceutical
Prior art date
Application number
GT201200284A
Other languages
English (en)
Inventor
Lulla Amar
Malhota Geena
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT201200284A publication Critical patent/GT201200284A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

UNA COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE EFAVIRENZ EN EL QUE EL EFAVIRENZ ES EN FORMA DE NANOPARTÍCULAS SE DA A CONOCER.
GT201200284A 2010-04-20 2012-10-18 Composición farmacéutica GT201200284A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1296MU2010 2010-04-20

Publications (1)

Publication Number Publication Date
GT201200284A true GT201200284A (es) 2014-08-26

Family

ID=44625957

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201200284A GT201200284A (es) 2010-04-20 2012-10-18 Composición farmacéutica

Country Status (13)

Country Link
US (1) US20130302415A1 (es)
EP (1) EP2560617A2 (es)
JP (1) JP2013525337A (es)
KR (1) KR20130076818A (es)
CN (1) CN102985072A (es)
AU (1) AU2011244783B2 (es)
BR (1) BR112012026843A2 (es)
CA (1) CA2796494A1 (es)
GT (1) GT201200284A (es)
NZ (1) NZ602955A (es)
RU (1) RU2012149115A (es)
WO (1) WO2011131943A2 (es)
ZA (1) ZA201207670B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201115633D0 (en) 2011-09-09 2011-10-26 Univ Liverpool Compositions of efavirenz
US10646452B2 (en) * 2013-03-15 2020-05-12 New Jersey Institute Of Technology System and method for fabrication of uniform polymer films containing nano and micro particles via continuous drying process
WO2015059466A1 (en) 2013-10-25 2015-04-30 Cipla Limited Pharmaceutical compositions comprising efavirenz
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
IN2014MU00916A (es) * 2014-03-20 2015-09-25 Cipla Ltd
CN104224790A (zh) * 2014-09-28 2014-12-24 苏州普罗达生物科技有限公司 一种依法韦仑组合物及其制备方法
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
GB201515391D0 (en) * 2015-08-28 2015-10-14 Amazentis Sa Compositions
GB201515387D0 (en) * 2015-08-28 2015-10-14 Amazentis Sa Compositions
AU2018306303A1 (en) 2017-07-25 2020-02-20 Elektrofi, Inc. Formation of particles including agents
ES2732498B2 (es) * 2018-05-21 2020-04-27 Consejo Superior Investigacion Uso de efavirenz para el tratamiento de enfermedades de almacenamiento lipidico.
KR20210019056A (ko) * 2018-06-11 2021-02-19 오츠카 세이야쿠 가부시키가이샤 델라마니드 함유 조성물
AU2020214626A1 (en) 2019-01-31 2021-09-16 Elektrofi, Inc. Particle formation and morphology
JP2022547546A (ja) 2019-09-13 2022-11-14 エレクトロフィ，インコーポレイテッド 疾患の処置のための治療用生物学的作用剤の送達のための組成物及び方法
CN112245400B (zh) * 2020-11-10 2023-01-20 蓝龙药业(北京)有限公司 一种依法韦仑微片剂、制备方法及其应用
CN114404377B (zh) * 2022-01-10 2023-07-25 安徽贝克生物制药有限公司 一种阿巴卡韦、拉米夫定、依非韦伦复方片及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72207C2 (uk) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
CO5070643A1 (es) 1998-05-27 2001-08-28 Merck & Co Inc Formulacion en tabletas comprimidas
EP1332757B1 (en) * 1998-05-27 2012-06-13 Merck Sharp & Dohme Corp. Efavirenz compressed tablet formulation
EP1448170A4 (en) * 2001-11-27 2010-05-12 Bristol Myers Squibb Co EFAVIRENZ STAMP PREPARATIONS HAVING UNIQUE BIOPHARMACEUTICAL CHARACTERISTICS
AR054806A1 (es) * 2005-06-29 2007-07-18 Wyeth Corp Formulaciones de estrogenos conjugados y bazedoxifeno
US20080026062A1 (en) * 2006-07-31 2008-01-31 Isaac Farr Pharmaceutical compositions including nano-sized active agent
TWI405590B (zh) * 2007-04-06 2013-08-21 Activus Pharma Co Ltd 微粉碎化有機化合物粒子之製法
EP2076248A2 (en) * 2007-08-17 2009-07-08 Teva Pharmaceutical Industries Ltd. Methods and compositions for controlling the bioavailability of poorly soluble drugs
JP4606444B2 (ja) * 2007-08-21 2011-01-05 アピ株式会社 アントシアニン含有経口投与用組成物及びその製造方法
WO2010068899A1 (en) * 2008-12-12 2010-06-17 Creighton University Nanoparticles comprising combinations of antiretroviral agents and use thereof
US10952965B2 (en) * 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
GB201006038D0 (en) * 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions

Also Published As

Publication number Publication date
NZ602955A (en) 2015-02-27
US20130302415A1 (en) 2013-11-14
WO2011131943A2 (en) 2011-10-27
WO2011131943A8 (en) 2012-11-29
ZA201207670B (en) 2013-05-29
RU2012149115A (ru) 2014-05-27
KR20130076818A (ko) 2013-07-08
CA2796494A1 (en) 2011-10-27
BR112012026843A2 (pt) 2016-07-12
EP2560617A2 (en) 2013-02-27
CN102985072A (zh) 2013-03-20
JP2013525337A (ja) 2013-06-20
WO2011131943A3 (en) 2011-12-29
AU2011244783B2 (en) 2015-11-12
AU2011244783A1 (en) 2012-11-01

Similar Documents

Publication Publication Date Title
GT201200284A (es) Composición farmacéutica
SMT201700008B (it) Composizione farmaceutica
CO6980625A2 (es) Composiciones que generan perácidos
BR112013007362A2 (pt) composição farmacêutica
CR20140450A (es) Composicion para el control de plagas que incluye un derivado de iminopiridina novedoso
CO7160079A2 (es) Composiciones líquidas de racecadotrillo
CU20100230A7 (es) Composición farmacéutica que comprende una sal de estroncio, vitamina d y una ciclodextrina
BR112013003536A2 (pt) composição, e utilização de uma composição.
BRPI1005931A2 (pt) associação de compostos, uso de uma associação, produto em forma de kit, uso de um produto e composição farmacêutica
BR112014001219A2 (pt) perfume
EE201300005A (et) Ravimkoostis
BR112013028039A2 (pt) composição de cimento
BR112013012313A2 (pt) combinação farmacêutica de paclitaxel e um inibidor de cdk
BR112013027403A2 (pt) composições que compreendem uma antimetabólito de glicose e selênio
FI20095987A0 (fi) Koneistojarru
AR082215A1 (es) Composicion farmaceutica agradable al paladar
CU24163B1 (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
BR112012020940A2 (pt) artigo fabricado com uma composição poliolefínica
BR112013011650A2 (pt) embalagem com rasgamento por pressão
CR20140375A (es) Superficie
BR112015004813A2 (pt) composição de sabão, método de desinfecção de uma superfície e utilizações de uma composição
DOP2013000258A (es) Formulaciones de liberación sostenida de paracetamol
BR112012029461A2 (pt) composição farmacêutica contendo solifenacina
HRP20130082A2 (hr) Farmaceutski pripravak za produljeno oslobađanje trimetazidina
BR112013033127A2 (pt) suplemento alimentar, composição alimentar e forma de dosagem